AC Immune soars on Alzheimer's drug trial results

A company logo hangs on the wall at the Roche Holding headquarters in Basel, Switzerland, on April 26, 2018. Foto: Stefan Wermuth/Bloomberg Photo

An experimental Alzheimer's therapy developed by AC Immune and Roche Holding slowed patients' rate of cognitive decline in a study, another hopeful sign for a field that has faced years of setbacks.

The antibody, known as semorinemab, targets a protein called tau that is thought to play a role in Alzheimer's. The treatment reduced cognitive decline from baseline by 43.6% compared to placebo in people with mild-to-moderate disease, AC Immune said Tuesday. Researchers didn't see an impact on functional decline, the other main target of the study, and the experimental drug failed to meet some secondary goals...

Læs også
Top job